{"id":112446,"date":"2019-10-10T17:47:57","date_gmt":"2019-10-10T17:47:57","guid":{"rendered":"https:\/\/stockchase.com\/discover\/?p=112446"},"modified":"2019-10-10T17:47:57","modified_gmt":"2019-10-10T17:47:57","slug":"top-biotech-and-pharma-stocks-to-bet-on-cancer-cure-control","status":"publish","type":"post","link":"https:\/\/stockchase.com\/discover\/top-biotech-and-pharma-stocks-to-bet-on-cancer-cure-control\/","title":{"rendered":"Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control"},"content":{"rendered":"

Cancer fighting drugs and therapy companies are poised to profit from long term aging trends of the population as well as the rise of cancer in general. There are now companies that are trying to personalize treatments with gene therapy. <\/p>\n

Here are Canadian and US companies that are producing innovative methods to control and cure cancer. <\/p>\n

👨‍⚕️ Healthcare<\/strong><\/p>\n

Canada Stocks<\/strong><\/p>\n

Oncolytics Biotech (ONC-T)<\/a>
\nA company that specializes in treating solid tutors. There is still a long way to go but the product has huge potential.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Oncolytics\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tOncolytics Biotech (ONC.TO)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about ONC.TO: Interesting technology. Trials are turning out well, but too small a sampling at this time. Speculative.<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Concordia International Corp (CXR-T)<\/a>
\nThe company focuses on treating ADHD, cancer and asthma. They went through a restructuring, along with many other Canadian drug manufacturers.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Concordia\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tConcordia International Corp (CXR.TO)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about CXR.TO: Concordia (CXR-T) or Valeant (VRX-T)? He wouldn\u2019t pick either because whenever you have accounting irregularities, that\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Medx Health Corp. (MDX-X)<\/a>
\nA company that has recently changed their President and CEO. It is a medical device manufacturer that helps diagnose skin cancer, and they are now entering Spanish-speaking countries.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Medx\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tMedx Health Corp. (MDX.V)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about MDX.V: Their numbers were up 13%. They have a device that looks at moles for Melanoma. They are now focusing on health and safety for\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

U.S Stocks<\/strong><\/p>\n

Amgen Inc. (AMGN-Q)<\/a>
\nA developer and manufacturer of biotechnology based therapy. They have several cancer fighting drugs in their repertoire including a new colorectal cancer drug. They have surpassed earning estimates in the last year and pays a dividend of 3%.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Amgen\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tAmgen Inc. (AMGN)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about AMGN: One of the oldest biotech companies in the world. Very big portfolio of products. Revenue last quarter up 9%, with 15 products\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Celgene Corp (CELG-Q)<\/a>
\nAn American biotech company that specializes in cancer and inflammatory disorder therapy. They are starting the process of merging with BMY-N. A good cash flow generator.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Celgene\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tCelgene Corp (CELG)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about CELG: They have a good cash float, which will lead to a share buyback, he feels. He sees resistance at $90-$100, which will be tough to\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Bristol Myers Squibb (BMY-N)<\/a>
\nThe company has several blockbuster immunotherapy drugs in their pipeline, as well as some chemotherapy products for leukaemia. The company has announced plans to acquire Celgene that will add several other high profile drugs.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Bristol\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tBristol Myers Squibb (BMY)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about BMY: Stock has been hot since the summer when the new CEO took over, then they got approval for their schizophrenia drugs. (Abbvie's\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Pfizer Inc (PFE-N)<\/a>
\nOne of the largest pharmaceutical companies in the world. It is currently in its seasonal weakness which is mid-October. It has enjoyed long term support levels and is consolidating well.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Pfizer\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tPfizer Inc (PFE)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about PFE: Pays a 6.9% dividend. The Covid vaccine days are long gone, so shares have been stuck around $25 for months. So, you still get a\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

AbbVie Inc. (ABBV-N)<\/a>
\nTheir blood cancer drug is projected to be one of the top best selling drugs in the world in the near future. The company also has other oncology drugs such as a top-selling immunology drug called Humira. They are currently in the process of acquiring Allergan.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"AbbVie\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tAbbVie Inc. (ABBV)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about ABBV: The drug companies are in the dog house. If you buy this, you must be patient. It yields 4%.<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Johnson & Johnson (JNJ-N)<\/a>
\nA global medical devices, pharmaceutical and consumer goods company. Their drugs are doing well and the company remains very profitable but volatile. They are going through a litigation for opiates and a ruling against their anti-psychotic drug.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Johnson\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tJohnson & Johnson (JNJ)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about JNJ: It reports Tuesday when we should get a legal update about those suing JNJ for cancer allegedly being in their talcum powder. It's\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Novartis AG (NVS-N)<\/a>
\n One of the world\u2019s largest pharmaceutical company based out of Switzerland. They sold off their ophthalmology business and are refocusing on generic drugs. The company also has many drugs that are close to approval that could become blockbuster drugs.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Novartis\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tNovartis AG (NVS)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about NVS: The global pharma industry is under this cloud. The whole subsector is really struggling. They have come off their bottoms, but\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

GlaxoSmithKline PLC (GSK-N)<\/a>
\nA British pharma company that is refocusing away from consumer products to pharmaceuticals. The company is doing well with 5% dividend. However, there is a hard brexit risk.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"GlaxoSmithKline\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tGlaxoSmithKline PLC (GSK)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about GSK: Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Astrazeneca P L C (AZN-N)<\/a>
\nA well diversified and global pharmaceutical company that specializes in oncology. They pay a great dividend and are focusing on less price-sensitive areas.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Astrazeneca\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tAstrazeneca P L C (AZN)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about AZN: Stockchase Research Editor: Michael O'Reilly We reiterate AZN as a TOP PICK. Recently reported earnings indicated a 19% increase\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Gilead Sciences Inc. (GILD-Q)<\/a>
\nAn American biopharmaceutical company. They consolidated for the last year and a half. The company is doing well, with a 4% yield. They have a history of blockbuster drugs with Hepatitis C and HIV.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Gilead\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tGilead Sciences Inc. (GILD)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about GILD: (A Top Pick Oct 27\/20, Up 6.6%)Stockchase Research Editor: Michael O\u2019Reilly Our PAST TOP PICK with GILD has triggered its stop at\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Regeneron Pharmaceuticals Inc (REGN-Q)<\/a>
\nA biotech company with good free cash flow. They have some drugs for niche markets. Their earnings don\u2019t come from one specific sector of their activity.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Regeneron\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tRegeneron Pharmaceuticals Inc (REGN)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about REGN: His favourite stock in his favourite sector. It is up 18% YTD. Expert opinions on Regeneron Pharmaceuticals Inc (REGN) \u2014 buy,\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

CRISPR Therapeutics AG (CRSP-Q)<\/a>
\nA smaller company that is developing gene medications. They have a gene-editing tool that has the potential to cure several diseases, including some cancers.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"CRISPR\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tCRISPR Therapeutics AG (CRSP)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about CRSP: They produce a gene-editing tool that splices DNA that has the potential of curing diseases such as Huntington's Chorea and\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Varian Medical Systems (VAR-N)<\/a>
\nThe company specializes in radiation therapy equipment to treat cancer. The trend for cancer radiation therapy is still positive and analysts think there will be an up-tick in sales.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Varian\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tVarian Medical Systems (VAR)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about VAR: Medical systems in the cancer field. Company has done brilliantly. Trading up near record levels. If he has stocks that have done\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Merck & Company (MRK-N)<\/a>
\nTheir main drugs are for treating diabetes and oncology. They have a great pipeline of new drugs that are coming up and will drive revenues over the long term. They pay a dividend of 2.65%
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Merck\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tMerck & Company (MRK)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about MRK: (A Top Pick Sep 02\/25, Up 9.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with MRK is progressing well. To\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Eli Lilly & Co. (LLY-N)<\/a>
\nA global pharmaceutical company that recently made an acquisition in oncology. It has been one of the best growth companies with a rate of 10% EPS.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Eli\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tEli Lilly & Co. (LLY)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about LLY: (A Top Pick Mar 19\/25, Up 29%) (Note the short timeframe.) Hitting all-time highs. At her original target price, which she's now\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n

Abbott Labs (ABT-N)<\/a>
\nA diversified healthcare company. It sells generic drugs to emerging markets. They also have medical devices and are diversified globally. A very safe play, especially considering that they have raised dividends for 47 years straight. Yield of 1.50%.
\n

\n\t\t\t
\n\t\t\t\t\n\t\t\t\t\t\"Abbott\t\t\t\t<\/span>\n\t\t<\/div>\n\t\n\t
\n\t\t\n\t\t\tAbbott Labs (ABT)\t\t<\/a>\n\t<\/div>\n\t
\n\t\t\n\t\t\t

Opinion about ABT: Diversified. Over 60% of sales come from outside US, so a more globally balanced name in the sector. 10\/10 on fundamentals.\u2026<\/p>\n\t\t<\/span>\n\t<\/div>\n\t

\n\t\t\"Stockchase\"\t\tStockchase\t<\/div>\n<\/div> <\/p>\n","protected":false},"excerpt":{"rendered":"

Cancer fighting drugs and therapy companies are poised to profit from long term aging trends of the population as well as the rise of cancer in general. There are now companies that are trying to personalize treatments with gene therapy. […]<\/p>\n","protected":false},"author":9,"featured_media":112640,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"cwp_meta_box_check":"No","cwp_rev_product_name":"","cwp_rev_product_image":"","wppr_links":[],"cwp_rev_price":"","wppr_options":[],"wppr_pros":[],"wppr_cons":[],"footnotes":""},"categories":[17],"tags":[],"class_list":["post-112446","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lists"],"wppr_data":{"cwp_meta_box_check":"No"},"_links":{"self":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts\/112446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/comments?post=112446"}],"version-history":[{"count":0,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/posts\/112446\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/media\/112640"}],"wp:attachment":[{"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/media?parent=112446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/categories?post=112446"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stockchase.com\/discover\/wp-json\/wp\/v2\/tags?post=112446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}